准核心:C9ORF72对抗剂作为肌缩性侧面硬化症治疗的先驱 - - 一种基于计算和机器学习的方法
K T Nachammai1, P Sangavi2,3, Chitra Sekar4
1Department of Biotechnology, Alagappa University, Karaikudi, Tamil Nadu 630003 India.
In silico pharmacology
|November 24, 2025
概括
研究人员使用虚拟查和分子动力学识别了潜在的C9ORF72对肌缩侧面硬化症 (ALS) 的agonists. 发现有前途的化合物可以增强运动神经元的稳定性和ALS治疗的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 计算化学计算化学
- 药物发现 药物发现 药物发现
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种进展性神经退行性疾病,影响运动神经元.
- 目前的ALS治疗有效性有限.
- 对运动神经元的衰老影响可能会导致ALS病理.
研究的目的:
- 为了识别和选潜在的C9ORF72对ALS的agonists.
- 使用高通量虚拟选和分子动力学模拟.
- 评估化合物的结合亲和力,稳定性和药理动力学特性.
主要方法:
- 化学数据库的高通量虚拟选.化学数据库的高通量虚拟选.
- 分子动力学 (MD) 模拟.
- 机器学习 (ML) 分析工具 (例如,pkCSM用于ADME/毒性).
主要成果:
- 从 Specs_1289,Zinc_67912153 和 Enamine_785152 数据库中确定了化合物.
- 实现了高的对接分数 (高达-11.06 kcal/mol) 和有利的结合能.
- MD模拟证实了结构稳定性和显著的键相互作用.
结论:
- 已识别的化合物显示出作为ALS的C9ORF72激动剂的潜力.
- 这些化合物表现出有利的稳定性,反应性和药理动力学特征.
- 确定的线索代表着针对ALS的有希望的治疗策略.
关键词:
肌缩性侧面硬化症 (AMLS) 是一种疾病.C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C9ORF72C进行对接和动态模拟.神经退行性疾病的神经退行性疾病虚拟选是一个虚拟的选.更多相关视频
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
9.1K
08:53Assay to Measure Nucleocytoplasmic Transport in Real Time within Motor Neuron-like NSC-34 Cells
Published on: May 16, 2017
9.1K
相关概念视频
01:24Parkinson's Disease: Treatment
953
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
953
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772